Gossamer Bio Inc (NASDAQ:GOSS) rose 7.7% during trading on Monday . The company traded as high as $21.60 and last traded at $21.38, approximately 484,539 shares traded hands during trading. An increase of 83% from the average daily volume of 264,643 shares. The stock had previously closed at $19.85.
GOSS has been the topic of a number of analyst reports. ValuEngine raised shares of Gossamer Bio from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Evercore ISI set a $30.00 price objective on shares of Gossamer Bio and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Zacks Investment Research cut shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Tuesday, August 20th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Gossamer Bio has an average rating of “Buy” and an average price target of $28.00.
The stock has a market cap of $1.41 billion and a PE ratio of -0.95. The company has a current ratio of 17.80, a quick ratio of 17.80 and a debt-to-equity ratio of 0.09. The business has a 50-day moving average price of $19.60 and a 200-day moving average price of $19.77.
In other news, insider Luisa Salter-Cid sold 50,000 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $19.88, for a total transaction of $994,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Fund V. Gp L.P. Omega sold 21,404 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $21.56, for a total value of $461,470.24. Company insiders own 23.30% of the company’s stock.
Large investors have recently made changes to their positions in the company. Alps Advisors Inc. purchased a new position in shares of Gossamer Bio during the 2nd quarter valued at approximately $3,059,000. BNP Paribas Arbitrage SA purchased a new position in Gossamer Bio in the 2nd quarter valued at $42,000. Marshall Wace North America L.P. purchased a new position in Gossamer Bio in the 1st quarter valued at $9,523,000. Redmile Group LLC purchased a new position in Gossamer Bio in the 1st quarter valued at $5,418,000. Finally, Federated Investors Inc. PA purchased a new position in Gossamer Bio in the 1st quarter valued at $15,992,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.
About Gossamer Bio (NASDAQ:GOSS)
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.
Recommended Story: How is inflation measured?
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.